Among the AML samples whose mutation profile and sequencing data were available, 3 (2.0%) had concurrent mutations in TET2, DNMT3A, and FLT3ITD, 8 (5.2%) showed concurrent mutations in DNMT3A and FLT3ITD, 10 (6.6%) had only FLT3ITD mutation, and 19 (12.6%) showed only DNMT3A mutation. Here, TET2 is linked to acute myeloid leukemia.